Revolution Medicines Is Up Nearly 140% in 2026. Is the Hot Biotech Stock Still a Buy?

Revolution Medicines' stock has surged nearly 140% in 2026 following positive phase 3 trial results for its lead cancer drug daraxonrasib, which showed a 13.2-month survival rate versus 6.7 months for standard chemotherapy in metastatic pancreatic cancer. The company is approaching regulatory review and has a strong pipeline, but remains pre-revenue with significant R&D losses. The stock is considered a compelling buy for growth investors willing to accept clinical-stage biotech risk, though cautious investors should wait for commercial-stage validation.